Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print January 11, 2008
DOI: 10.2337/db07-0617

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0617v1
57/4/817    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Li, Y.
Right arrow Articles by Wang, X.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.
Right arrow Articles by Wang, X.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Homocysteine upregulates resistin production from adipocytes in vivo and in vitro

Yin Li, MD, PhD, Changtao Jiang, MD, Guoheng Xu, MD, PhD, Nanping Wang, MD, PhD, Yi Zhu, MD, PhD, Chaoshu Tang, MD, PhD, and Xian Wang, MD, PhD

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing 100083, P. R. China

Objective: Homocysteine (Hcy) is epidemiologically related to insulin resistance, which has been speculated as a low-grade systemic inflammatory condition. Resistin acts as a critical mediator of insulin resistance associated with inflammatory conditions. We aimed to determine whether Hcy can induce insulin resistance by directly regulating the expression and secretion of resistin from adipose tissue.

Research Design and Methods: The effect of Hcy on the expression and secretion of resistin and insulin resistance was investigated using primary rat adipocytes and mice with hyperhomocysteinemia (HHcy).

Results: Hcy impaired glucose transport and particularly the insulin signaling pathway as shown by decreased insulin-stimulated tyrosine phosphorylation of IR and IRS-1, increased serine phosphorylation of IRS-1, and inhibited Akt phosphorylation both in vitro and in vivo, and these impairments were accompanied by an increase in resistin expression. Compared with normal mice, HHcy mice with a clinically relevant level of plasma Hcy (19 µM) showed significantly increased resistin production from adipose tissue (33.38±3.08 vs 19.27±1.71 ng/ml, P<0.01). Hcy (300-1000 µM) also increased the mRNA expression of resistin in primary rat adipocytes in a time- and concentration-dependent manner, with maximal induction at 24 h of approximately 4-fold with 1000 µM. In addition, Hcy-induced resistin expression attenuated by treatment with reactive oxygen species (ROS) scavengers, protein kinase C (PKC) and nuclear factor (NF)-{kappa}B inhibitors implies a role in the process for ROS, PKC, and NF-{kappa}B.

Conclusions: HHcy may promote insulin resistance through the induction of resistin expression and secretion from adipocytes via the activation of the ROS-PKC-NF-{kappa}B pathway.


Correspondence: xwang{at}bjmu.edu.cn


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.